Analysts consider potential of Bristol-Myers' diabetes drugs

09/14/2007 | Bloomberg

The diabetes treatments that Bristol-Myers Squibb Co. is partnering with other drugmakers to develop each could take in $1 billion a year in sales, analysts say. Pfizer and AstraZeneca will participate in making two of the new drugs, which are expected to introduce a different approach to diabetes treatment. The strategy also will help the drugmaker recover from the patent expiration of its blockbuster drug Plavix in 2011.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC